ACB Aurora Cannabis Inc

 

  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2024

Commission File No. 001-38691

AURORA CANNABIS INC.
(Translation of registrant's name into English)

 

2207 90B St. SW,

Edmonton, Alberta,

Canada T6X 1V8
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  ☐ Form 40-F  ☒

 

 

 

INCORPORATION BY REFERENCE

 

This Form 6-K is hereby filed and incorporated by reference in the registrant’s Registration Statement on Form F-10 (File No. 333-271479).

 

 

 

SUBMITTED HEREWITH

 

Exhibits		Description
99.1		Material Change Report dated February 15, 2024

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AURORA CANNABIS INC.

/s/ Glen Ibbott

Glen Ibbott
Chief Financial Officer

Date: February 15, 2024

Exhibit 99.1 

 

 

 

FORM 51-102F3

MATERIAL CHANGE REPORT

 

Item 1 Name and Address of Company

 

Aurora Cannabis Inc. (“Aurora” or the “Company”)

2207-90b Street SW

Edmonton, Alberta

T6X 1V8

 

Item 2 Date of Material Change

 

February 7, 2024

 

Item 3 News Release

 

A press release describing the material change was disseminated by Aurora on February 8, 2024 through Cision PR Newswire and can be found on SEDAR+ at www.sedarplus.ca.

 

Item 4 Summary of Material Change

 

A wholly-owned subsidiary (“Aurora Sub”) acquired the remaining approximately 90% equity interest that Aurora did not previously own of Indica Industries Pty Ltd (“MedReleaf Australia”), a leading distributor of medical cannabis products, for an enterprise value of AUD$50 million, subject to customary adjustments. Aurora paid AUD$9.45 million in cash with the balance of the purchase price satisfied by the issuance of common shares of Aurora (the “Aurora Shares”).

 

Item 5 Full Description of Material Change

 

5.1        Full Description of Material Change

 

On February 7, 2024, Aurora, through Aurora Sub, purchased the remaining approximately 90% equity interest of MedReleaf Australia at a total enterprise value of AUD$50 million subject to customary adjustments (the “Transaction”). As consideration, Aurora (i) issued the selling shareholders an aggregate of 69,489,941 Aurora Shares (the “Share Consideration”); and (ii) paid the selling shareholders AUD$9.45 million in cash (the “Cash Consideration” and together with the Share Consideration, the “Consideration”), subject to customary adjustments post-closing. Approximately 10% of the Consideration will be held in escrow to ensure certain obligations of the selling shareholders.

 

5.2        Disclosure for Restructuring Transactions

 

Not applicable.

 

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

 

Not applicable.

 

 

 

Item 7 Omitted Information

 

Not applicable.

 

Item 8 Executive Officer

 

Further information regarding the matters described in this report may be obtained from Ananth Krishnan, Vice President, Strategic Finance, who is knowledgeable about the details of the Transaction and may be contacted at Ananth.krishnan@auroramj.com.

 

Item 9 Date of Report

 

February 15, 2024.

---